Immunic (IMUX) Scheduled to Post Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is set to announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same quarter last year, the business earned ($0.54) earnings per share. On average, analysts expect Immunic to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immunic Price Performance

NASDAQ IMUX opened at $1.19 on Wednesday. The business has a fifty day moving average of $1.49 and a 200-day moving average of $1.35. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $2.11.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th. B. Riley started coverage on Immunic in a report on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price on the stock. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $5.00 price target on shares of Immunic in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $11.20.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.